Skip to main content
Top
Published in: Intensive Care Medicine 3/2010

01-03-2010 | Brief Report

Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection

Authors: Paul Robert Ingram, Tim Inglis, David Moxon, David Speers

Published in: Intensive Care Medicine | Issue 3/2010

Login to get access

Abstract

Purpose

To examine whether, in an adult intensive care unit (ICU), procalcitonin or C-reactive protein (CRP) levels discriminated between 2009 H1N1 influenza infection and community-acquired pneumonia of bacterial origin.

Methods

A retrospective observational study performed at an Australian hospital over a 4-month winter period during the 2009 H1N1 influenza pandemic. Levels on admission of procalcitonin and CRP were compared between patients admitted to the ICU with community-acquired pneumonia of bacterial and 2009 H1N1 origin.

Results

Compared to those with bacterial or mixed infection (n = 9), patients with 2009 H1N1 infection (n = 16) were significantly more likely to have bilateral chest X-ray infiltrates, lower APACHE scores, more prolonged lengths of stay in ICU and lower white cell count, procalcitonin and CRP levels. Using a cutoff of >0.8 ng/ml, the sensitivity and specificity of procalcitonin for detection of patients with bacterial/mixed infection were 100 and 62%, respectively. A CRP cutoff of >200 mg/l best identified patients with bacterial/mixed infection (sensitivity 100%, specificity 87.5%). In combination, procalcitonin levels >0.8 ng/ml and CRP >200 mg/l had optimal sensitivity (100%), specificity (94%), negative predictive value (100%) and positive predictive value (90%). Receiver-operating characteristic curve analysis suggested the diagnostic accuracy of procalcitonin may be inferior to CRP in this setting.

Conclusions

Procalcitonin measurement potentially assists in the discrimination between severe lower respiratory tract infections of bacterial and 2009 H1N1 origin, although less effectively than CRP. Low values, particularly when combined with low CRP levels, suggested bacterial infection, alone or in combination with influenza, was unlikely.
Literature
1.
go back to reference ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361:1991–1993CrossRef ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361:1991–1993CrossRef
2.
go back to reference Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, van de Vijver D, Boucher CA, Koopmans M, Rimmelzwaan GF, Kuiken T, Osterhaus AD, Fouchier RA (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481–483PubMed Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, van de Vijver D, Boucher CA, Koopmans M, Rimmelzwaan GF, Kuiken T, Osterhaus AD, Fouchier RA (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481–483PubMed
3.
go back to reference Niederman M (2008) Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 47:S127–S132CrossRefPubMed Niederman M (2008) Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 47:S127–S132CrossRefPubMed
4.
go back to reference Erratum (2005) Clin Infect Dis 40:1386–1388 Erratum (2005) Clin Infect Dis 40:1386–1388
5.
go back to reference Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, ProHOSP Study Group (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections. JAMA 302:1059–1066CrossRefPubMed Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, ProHOSP Study Group (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections. JAMA 302:1059–1066CrossRefPubMed
6.
go back to reference Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, Ravilly S, Lefèvre H, Royer C, Lacombe C, Palmer P, Bohuon C (1999) Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial versus viral infections. Pediatr Infect Dis J 18:875–881CrossRefPubMed Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, Ravilly S, Lefèvre H, Royer C, Lacombe C, Palmer P, Bohuon C (1999) Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial versus viral infections. Pediatr Infect Dis J 18:875–881CrossRefPubMed
7.
go back to reference Masiá M, Gutiérrez F, Padilla S, Soldán B, Mirete C, Shum C, Hernández I, Royo G, Martin-Hidalgo A (2007) Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 13:153–161CrossRefPubMed Masiá M, Gutiérrez F, Padilla S, Soldán B, Mirete C, Shum C, Hernández I, Royo G, Martin-Hidalgo A (2007) Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 13:153–161CrossRefPubMed
8.
go back to reference Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernández I (2005) Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 128:2223–2229CrossRefPubMed Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernández I (2005) Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 128:2223–2229CrossRefPubMed
9.
go back to reference Tang BM, Eslick GD, Craig JC, McLean AS (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–217CrossRefPubMed Tang BM, Eslick GD, Craig JC, McLean AS (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–217CrossRefPubMed
10.
go back to reference Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG (2009) Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci 106:3455–3460CrossRefPubMed Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, García-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG (2009) Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci 106:3455–3460CrossRefPubMed
11.
go back to reference Christ-Cain M, Muller B (2007) Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 30:556–573CrossRef Christ-Cain M, Muller B (2007) Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 30:556–573CrossRef
12.
go back to reference Chua A, Lee K (2004) Procalcitonin in severe acute respiratory syndrome (SARS). J Infect 48:303–306CrossRefPubMed Chua A, Lee K (2004) Procalcitonin in severe acute respiratory syndrome (SARS). J Infect 48:303–306CrossRefPubMed
13.
go back to reference Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217CrossRefPubMed Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217CrossRefPubMed
14.
go back to reference Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D (2001) Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 84:332–336CrossRefPubMed Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D (2001) Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 84:332–336CrossRefPubMed
15.
go back to reference Korppi M (2004) Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination? Pediatr Int 46:545–550CrossRefPubMed Korppi M (2004) Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination? Pediatr Int 46:545–550CrossRefPubMed
16.
go back to reference Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 177:498–505CrossRefPubMed Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 177:498–505CrossRefPubMed
17.
go back to reference Boussekey N, Leroy O, Georges H, Devos P, d’Escrivan T, Guery B (2005) Diagnostic and prognostic values of admission and procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 33:257–263CrossRefPubMed Boussekey N, Leroy O, Georges H, Devos P, d’Escrivan T, Guery B (2005) Diagnostic and prognostic values of admission and procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 33:257–263CrossRefPubMed
Metadata
Title
Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection
Authors
Paul Robert Ingram
Tim Inglis
David Moxon
David Speers
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 3/2010
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-009-1746-3

Other articles of this Issue 3/2010

Intensive Care Medicine 3/2010 Go to the issue